Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

NCT04493138 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Recurrent Myeloproliferative Neoplasm

Interventions

DRUG: Azacitidine
DRUG: Quizartinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]